Unknown

Dataset Information

0

Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice.

ABSTRACT: An effective vaccine is essential for controlling the spread of the SARS-CoV-2 virus. Here, we describe an influenza virus-based vaccine for SARS-CoV-2. We incorporated a membrane-anchored form of the SARS-CoV-2 spike receptor binding domain (RBD) in place of the neuraminidase (NA) coding sequence in an influenza virus also possessing a mutation that reduces the affinity of hemagglutinin for its sialic acid receptor. The resulting ΔNA(RBD)-Flu virus can be generated by reverse genetics and grown to high titers in cell culture. A single-dose intranasal inoculation of mice with ΔNA(RBD)-Flu elicits serum neutralizing antibody titers against SAR-CoV-2 comparable to those observed in humans following natural infection (~1:200). Furthermore, ΔNA(RBD)-Flu itself causes no apparent disease in mice. It might be possible to produce a vaccine similar to ΔNA(RBD)-Flu at scale by leveraging existing platforms for the production of influenza vaccines.

SUBMITTER: Loes AN 

PROVIDER: S-EPMC7552029 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice.

Loes Andrea N AN   Gentles Lauren E LE   Greaney Allison J AJ   Crawford Katharine H D KHD   Bloom Jesse D JD  

Viruses 20200905 9

An effective vaccine is essential for controlling the spread of the SARS-CoV-2 virus. Here, we describe an influenza virus-based vaccine for SARS-CoV-2. We incorporated a membrane-anchored form of the SARS-CoV-2 spike receptor binding domain (RBD) in place of the neuraminidase (NA) coding sequence in an influenza virus also possessing a mutation that reduces the affinity of hemagglutinin for its sialic acid receptor. The resulting ΔNA(RBD)-Flu virus can be generated by reverse genetics and grown  ...[more]

Similar Datasets

Unknown Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice.
| S-EPMC7430565 | biostudies-literature
Unknown Structures from "Engineering Neutralizing SARS-CoV Antibodies to Bind SARS-CoV-2"
| S-BSST379 | biostudies-other
Unknown An influenza virus vector candidate vaccine stably expressing SARS-CoV-2 receptor-binding domain produces high and long-lasting neutralizing antibodies in mice.
| S-EPMC9181763 | biostudies-literature
Genomics Potent neutralizing antibodies against SARS-CoV-2
| EGAS00001004412 | EGA
Unknown Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.
| S-EPMC7506210 | biostudies-literature
Unknown Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.
| S-EPMC3356997 | biostudies-literature
Unknown Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies.
| S-EPMC7547570 | biostudies-literature
Unknown A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain.
| S-EPMC8113771 | biostudies-literature
Unknown Point mutations in SARS-CoV-2 variants induce long-range dynamical perturbations in neutralizing antibodies.
| S-EPMC9214918 | biostudies-literature
Unknown SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1.
| S-EPMC8387217 | biostudies-literature